Current clinical trials in the UK
Below is a list of clinical trials currently being carried out or planned in the near future in the UK. If you are eligible and interested in participating in one of these trials, you should speak to your consultant or a member of your care team in the first instance.
Note that the information included in the list below has been taken from the trial documentation as posted on the websites listed under 'further info' for each trial.
The inclusion of a trial (or the order of its inclusion) on the list below does not imply that the Cystic Fibrosis Trust recommends participation in it or in any one trial over another. For more information about whether to participate in a clinical trial, see our Taking part in a clinical trial page.
Clinical trials currently recruiting
A study of donor lung perfusion in lung transplantation in United Kingdom (DEVELOP-UK)
The DEVELOP-UK study is designed to investigate the clinical effectiveness and cost effectiveness of a new technology called ex-vivo lung perfusion or EVLP. EVLP is a novel technique in which unusable donor lungs which are functioning poorly or in which function is uncertain, can be carefully assessed and potentially improved for safe use in clinical lung transplantation.
| Study intervention: | Ex-vivo lung perfusion |
| Study ages: | 18 years and older |
| Type of
therapy: | Lung transplant |
Study to Evaluate Arikace™ in CF Patients With Chronic Pseudomonas aeruginosa Infections
The purpose of this European Registration study is to determine whether Arikace™ is effective in treating chronic lung infections caused by Pseudomonas aeruginosa in Cystic Fibrosis subjects. The effectiveness, safety and tolerability of Arikace™ will be compared to TOBI, an inhalation antibiotic already available for use.
| Study
drugs: | Arikace™ |
|
Study ages: | 6 years and older |
| Type of
therapy: | Anti-infective |
A Safety and Tolerability Study OF PUR118 In Subjects With Cystic Fibrosis
The purpose of this study is to determine whether PUR118 is safe and tolerable in a population of subjects with Cystic Fibrosis.
| Study
drugs: | PUR118 |
|
Study ages: | 18-55 years |
| Type of
therapy: | Anti-inflammatory |
A Cross-over Study of OligoG in Subjects with Cystic Fibrosis
The purpose of this study is to determine the safety and local tolerability of multiple dose administration of inhaled OligoG in CF subjects.
| Study
drugs: | OligoG CF-5/20 |
|
Study ages: | 18 years and older |
| Type of
therapy: | Combination (airway clearance / anti-infective |
Circadian Rhythm in Tobramycin Elimination in Cystic Fibrosis (CRITIC)
Phase IV study. The investigators have preliminary data that suggests that administering tobramycin in the morning may be safer for the kidneys than administering it in the evening. If the preliminary data are proved correct, this research will allow investigators to improve the safety profile of tobramycin, one of the most widely prescribed drugs in Cystic Fibrosis.
| Study
drugs: | Tobramycin |
|
Study ages: | 5 years and
older |
| Type of
therapy: | Anti-infective |
The Infective Pulmonary Exacerbations in Cystic Fibrosis - an Ecological Perspective
This study will examine 3 areas of interest in CF exacerbations.
- Bacterial biodiversity and its clinical significance
- The role of bacteria which are able to rapidly mutate (hypermutators)
- Inter-bacterial communication and its role in infective exacerbations
| Study drugs: | N/A |
|
Study ages: | 16 years and older |
| Type of therapy: | N/A |
Ghrelin in Cystic Fibrosis
The purpose of this study is to investigate the role of a naturally occuring hormone called ghrelin on appetite, energy expenditure and immune function in patients with Cystic Fibrosis.
| Study drugs: | Ghrelin |
| Study ages: | 18 to 80 years |
| Type
of therapy: | Hormone (increases food intake) |
TORPEDO-CF Trial of Optimal Therapy for Pseudomonas Eradication in Cystic Fibrosis
This trial will assess whether ten days intravenous ceftazidime with tobramycin is superior to three months oral ciprofloxacin. Both treatment regimes will be in conjunction with three months nebulised colistin.
| Study drugs: | Ceftazidime, tobramycin, ciprofloxacin |
|
Study ages: | NA |
| Type
of therapy: | Anti-infective |
Extension Study of Ataluren (PTC124™) in Cystic Fibrosis (recruiting by invitation only)
This study is a Phase III extension trial that will evaluate the long-term safety of ataluren (PTC124) in adult and pediatric patients with nonsense mutation CF, as determined by adverse events and laboratory abnormalities. The study will also assess changes in pulmonary function, CF pulmonary exacerbations, health-related quality of life, antibiotic use for CF-related infections, CF-related disruptions to daily living, body weight, and CF pathophysiology.
| Study drugs: | Ataluren (PTC124™) |
|
Study ages: | 6 years and older |
| Type
of therapy: | CFTR modulation |
Clinical trials ongoing (recruitment closed)
Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients
High concentrations of Aeroquin (MP-376) delivered directly to the lung are projected to have antimicrobial effects on even the most resistant organisms. This phase 3, open-label, randomized trial will evaluate the safety and efficacy of MP-376 Inhalation Solution vs. Tobramycin Inhalation Solution (TIS) in stable CF patients.
| Study drugs: | Aeroquin (MP-376), Tobramycin |
|
Study ages: | 12 years and older |
| Type of therapy: | Anti-infective |
The use of High Frequency Chest Wall Oscillation during an acute infective pulmonary exacerbation of Cystic Fibrosis
(The Vest® Airway Clearance System)
This phase III study aims to test the hypothesis addition of high frequency chest wall oscillation to twice daily supervised physiotherapy is as effective as the addition of self treatment in facilitating recovery from an acute infective pulmonary exacerbation, as measured by improvement in lung function, specifically forced expiratory volume in one second (FEV1).
| Study drugs: | N/A |
|
Study ages: | 16 years and older |
| Type
of therapy: | Airway clearance therapy |
Study of VX-770 in Cystic Fibrosis Subjects
This phase III study will enroll subjects with CF who have completed Study VX08-770-102 (Study 102) and Study VX08-770-103 (Study 103) to further evaluate the safety and efficacy of long term VX-770 treatment.
| Study drugs: | VX-770 |
|
Study ages: | 6 years and older |
| Type
of therapy: | CFTR modulation |
Study of VX-770 in Cystic Fibrosis subjects age 12 and older with the G551D mutation
A phase III, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of VX-770 in subjects with Cystic Fibrosis and the G551D mutation.
| Study drugs: | VX-770 |
|
Study ages: | 12 to 70 years old |
| Type
of therapy: | CFTR modulation |
Study of Ataluren (PTC124™) in Cystic Fibrosis
Phase III, multi-centre, randomized, double-blind, placebo-controlled, efficacy and safety study, designed to document the clinical benefit of Ataluren (PTC124) when administered as therapy of patients with CF due to a nonsense mutation (premature stop codon) in the CFTR gene. At the completion of blinded treatment, all compliant participants will be eligible to receive open-label Ataluren (PTC124) in a separate extension study.
| Study drugs: | Ataluren (PTC124™) |
|
Study ages: | 6 years and older |
| Type
of therapy: | CFTR modulation |
Clinical trials not yet recruiting
ATCF (Azole Therapy in Cystic Fibrosis)
Aspergillus infection is an infectious complication which frequently occurs in cystic fibrosis. The efficacy of azole therapy in patients with cystic fibrosis with persistent positive sputums for Aspergillus is still unknown. Furthermore, the efficacy of itraconazole and voriconazole in this indication has never been evaluated in a large prospective controlled clinical trial, even though many teams already use it. The ATCF study aims to assess in patients with cystic fibrosis with persistent Aspergillus positive cultures the efficacy of itraconazole and voriconazole on the negativisation of the sputum cultures for Aspergillus.
| Study drugs: | Itraconazole/voriconazole |
|
Study ages: | 12 years and older |
| Type
of therapy: | Anti-infective |
The Role of Respiratory Viruses in Exacerbations of Cystic Fibrosis in Adults
This study will identify the frequency of common viral infections in adults with CF and determine the effects they have on lung function, the rate and diversity of bacterial infection and patients' treatment burden. The information gained from this study will lead to improved prevention and treatment of respiratory infections in CF.
| Study drugs: | N/A - Observational study |
|
Study ages: | 18 years and older |
| Type
of therapy: | Airway clearance therapy |
Duration of antibiotics in infective exacerbations of Cystic Fibrosis
This phase IV trial is a double blinded, randomised trial with patients randomised to 10,14 or 21 days of antibiotic therapy, comprising of tobramycin and either ceftazidime or meropenem.
| Study drugs: | Ceftazidime, Tobramycin, Meropenem |
|
Study ages: | 16 years and older |
| Type
of therapy: | Anti-infective |
For an explanation of the different types of clinical trials, see our section on How clinical trials work.
Page last updated 01 May 2012
